Pancreatic Cancer Research

ResearcherDuke UniversityActive in the last 2 years

Mohamed A. Adam

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0059-7615; OpenAlex author ID A5051729464. Sources: OpenAlex.

Their work

Papers
19 (first author 3, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
40
Papers, trials and grants by year

2016: 1 paper · 2017: 3 papers · 2018: none · 2019: none · 2020: 2 papers · 2021: 4 papers · 2022: none · 2023: none · 2024: 3 papers · 2025: 1 paper · 2026: 5 papers

Papers 19

  1. Impact of adjuvant chemotherapy among pathologic complete responders with pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.ejso.2026.111955↗
  2. A Computer Vision Algorithm to Predict Superior Mesenteric Artery Margin Status for Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000006506↗
  3. Re-evaluating the Role of Neoadjuvant Chemotherapy in Early-Stage Pancreatic Ductal Adenocarcinoma: Unveiling the Impact of Immortal Time Bias on Survival. Last author DOI 10.1245/s10434-026-19829-1↗
  4. ASO Visual Abstract: Re-evaluating the Role of Neoadjuvant Chemotherapy in Early-Stage Pancreatic Ductal Adenocarcinoma: Unveiling the Impact of Immortal Time … Last author DOI 10.1245/s10434-026-19921-6↗
  5. ASO Author Reflection: Are Survival Gains with Neoadjuvant Therapy in Resectable PDAC Real? The Hidden Impact of Immortal Time Bias. Last author DOI 10.1245/s10434-026-19963-w↗
  6. Ongoing Failure to Deliver Guideline-Concordant Care for Patients with Pancreatic Cancer. Last author DOI 10.3390/cancers17020170↗
  7. Long-Duration Neoadjuvant Therapy with FOLFIRINOX Yields Favorable Outcomes for Patients Who Undergo Surgery for Pancreatic Cancer. Co-author DOI 10.1245/s10434-024-15579-0↗
  8. Distinct Indications for Adjuvant Therapy in Resected Invasive Mucinous Cystic Neoplasms of the Pancreas Compared with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-024-15841-5↗
  9. Adult Pancreatoblastoma: Clinical Insights and Outcomes Compared to Pancreatic Ductal Adenocarcinoma (PDAC). Last author DOI 10.3390/curroncol31090370↗
  10. Neoadjuvant therapy versus upfront surgery for early-stage left-sided pancreatic adenocarcinoma: A propensity-matched analysis from a national cohort of distal… First author DOI 10.1002/jso.26267↗
  11. Safety and oncologic efficacy of robotic compared to open pancreaticoduodenectomy after neoadjuvant chemotherapy for pancreatic cancer. Co-author DOI 10.1007/s00464-020-07638-w↗
  12. Neoadjuvant Chemotherapy for Pancreatic Adenocarcinoma Lessens the Deleterious Effect of Omission of Adjuvant Chemotherapy. Co-author DOI 10.1245/s10434-020-09446-x↗
  13. ASO Author Reflections: Neoadjuvant Chemotherapy for Pancreatic Adenocarcinoma Lessens the Deleterious Effect of Omission of Adjuvant Chemotherapy. Co-author DOI 10.1245/s10434-020-09487-2↗
  14. Long-term oncologic outcomes of robotic and open pancreatectomy in a national cohort of pancreatic adenocarcinoma. Co-author DOI 10.1002/jso.25958↗
  15. Improved overall survival is still observed in patients receiving delayed adjuvant chemotherapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Co-author DOI 10.1016/j.hpb.2020.03.006↗
  16. Nationwide trends and outcomes associated with neoadjuvant therapy in pancreatic cancer: An analysis of 18 243 patients. Co-author DOI 10.1002/jso.24630↗
  17. Impact of minimally invasive vs. open distal pancreatectomy on use of adjuvant chemoradiation for pancreatic adenocarcinoma. First author DOI 10.1016/j.amjsurg.2017.01.005↗
  18. Going the Extra Mile: Improved Survival for Pancreatic Cancer Patients Traveling to High-volume Centers. Co-author DOI 10.1097/sla.0000000000001924↗
  19. Minimally Invasive Pancreaticoduodenectomy Does Not Improve Use or Time to Initiation of Adjuvant Chemotherapy for Patients With Pancreatic Adenocarcinoma. First author DOI 10.1245/s10434-015-4937-x↗

Closest collaborators

The 25 strongest of 40 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Adnan A. Alseidi · 8 shared papers, 2024–2026 · strength 1.91
  2. Eric K. Nakakura · 7 shared papers, 2024–2026 · strength 1.67
  3. Amir Ashraf‐Ganjouei · 5 shared papers, 2024–2026 · strength 1.45
  4. Kimberly Saunders Kirkwood · 4 shared papers, 2024–2026 · strength 0.86
  5. Jane Wang · 4 shared papers, 2024–2026 · strength 0.83
  6. Alessandro Paniccia · 5 shared papers, 2020–2021 · strength 0.82
  7. Sophia Hernandez · 3 shared papers, 2025–2026 · strength 0.82
  8. Amir Ashraf · 2 shared papers, 2026 · strength 0.58
  9. Ajay V. Maker · 3 shared papers, 2024 · strength 0.57
  10. Amer H. Zureikat · 4 shared papers, 2020–2021 · strength 0.54
  11. Ibrahim Nassour · 4 shared papers, 2020–2021 · strength 0.54
  12. Richard S. Hoehn · 3 shared papers, 2020–2021 · strength 0.41
  13. Dan German Blazer · 4 shared papers, 2016–2020 · strength 0.34
  14. Seif Elmankabadi · 1 shared paper, 2026 · strength 0.29
  15. Samer T. Tohme · 2 shared papers, 2020–2021 · strength 0.27
  16. Nathan Bahary · 2 shared papers, 2021 · strength 0.27
  17. David L. Bartlett · 2 shared papers, 2020–2021 · strength 0.25
  18. J. Ejie · 1 shared paper, 2025 · strength 0.24
  19. Timothy R. Donahue · 1 shared paper, 2026 · strength 0.24
  20. Neema Jamshidi · 1 shared paper, 2026 · strength 0.24
  21. Julie Ann Sosa · 3 shared papers, 2016–2017 · strength 0.23
  22. Daniel P. Nussbaum · 3 shared papers, 2016–2017 · strength 0.22
  23. Paul Wong · 1 shared paper, 2024 · strength 0.21
  24. Han Yin · 1 shared paper, 2024 · strength 0.18
  25. June S. Peng · 1 shared paper, 2024 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.